Stay updated on Nemtabrutinib in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Nemtabrutinib in Hematologic Malignancies Clinical Trial page.

Latest updates to the Nemtabrutinib in Hematologic Malignancies Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. No content or study data changes are included.SummaryDifference0.0%

- Check21 days agoChange DetectedThe Publications section now clarifies that entries are provided voluntarily by the data submitter and may be auto-filled from PubMed. The revision note records v3.3.1, replacing the previous v3.2.0 wording.SummaryDifference0.1%

- Check29 days agoChange DetectedThe site-wide notice about potential delays due to a lapse in government funding at the top of the ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check43 days agoChange DetectedThe update appears to be minor UI adjustments and an updated timestamp, with core study details, eligibility criteria, dosing, endpoints, and locations unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check71 days agoChange Detected- Added a funding/status notice and updated to v3.2.0. - Removed the term ‘Richter syndrome’ and old version reference v3.1.0.SummaryDifference2%

- Check79 days agoChange DetectedCore terminology updated: 'Diffuse large B-cell lymphoma' is replaced with 'Malignant lymphoma, large B-cell, diffuse' and the page version advances from v3.0.2 to v3.1.0.SummaryDifference0.5%

Stay in the know with updates to Nemtabrutinib in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nemtabrutinib in Hematologic Malignancies Clinical Trial page.